Program
SYS6006 COVID-19 vaccine
Also written as “20 μg dose of SYS6006”, “30 μg dose of SYS6006” and “SYS6006”.
Its studies are mostly in COVID-19, led by CSPC Pharmaceutical Group.
Furthest: phase 2, since Jun 27, 20224 company-led studies, 4 open or runningNext primary completion: Dec 31, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSPC Pharmaceutical Group | 44 open or running | phase 2since Jun 27, 2022 | Apr 28, 2022 | Dec 31, 2028phase 2 · NCT07622225 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 28, 2022First studies: 2 phase 1 studies in SARS-CoV-2First studyNCT05354089, NCT05354063
- Jun 27, 2022Phase 2 study in COVID-19NCT05439824 · 450 enrolled · China
- May 17, 2026Phase 2 study in Advanced Solid TumorsNCT07622225 · 264 planned
Ahead
- Dec 31, 2028Primary completion: phase 2 study in Advanced Solid TumorsNCT07622225
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07622225Advanced Solid Tumors | 2 | Not yet recruiting | Dec 31, 2028 | 264 |
| NCT05439824COVID-19 · China | 2 | Active, not recruiting | Jan 12, 2023 | 450 |
| NCT05354089SARS-CoV-2 · China | 1 | Active, not recruiting | Jul 9, 2022 | 40 |
| NCT05354063SARS-CoV-2 · China | 1 | Active, not recruiting | Sep 5, 2022 | 40 |
How it is read
Names in the registry
- “20 μg dose of SYS6006”, 2 entries
- “30 μg dose of SYS6006”, 2 entries
- “SYS6006”, 1 entry
- “SYS6006 20 μg”, 1 entry
- “SYS6006 30 μg”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.